⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078808 | 0.70 | — | — | |
| SCHEMBL3450079 | 0.57 | — | — | |
| SCHEMBL3635794 | 0.56 | — | — | |
| SCHEMBL208333 | 0.55 | — | — | |
| SCHEMBL207586 | 0.52 | — | — | |
| Hydrochloric Acid SCHEMBL7938304 | 0.50 | — | — | |
| Hydrochloric Acid SCHEMBL7938305 | 0.48 | — | — | |
| SCHEMBL8911746 | 0.31 | — | — | |
| Hydrochloric Acid SCHEMBL6244319 | 0.31 | — | — | |
| Hydrochloric Acid SCHEMBL1449238 | 0.31 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119630662-A | CBL-B inhibitors and methods of use thereof | 英矽智能科技知识产权有限公司 | 2025-03-14 | — | — | CN | claimed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | claimed |
| EP-3031324-A2 | TRICYCLIC KINASE INHIBITORS | AbbVie Inc. (US) | 2016-06-15 | — | — | EP | claimed |
| EP-2299821-B1 | TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | claimed |
| EP-2299821-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2011-03-30 | — | — | EP | claimed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | claimed |
| WO-2009152133-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | WO | claimed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12421232-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3768267-B1 | BETA-CARBOLINE DERIVATIVES AS DYRK1A INHIBITORS FOR THE TREATMENT OF E.G. DIABETES | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119630662-A | CBL-B inhibitors and methods of use thereof | 英矽智能科技知识产权有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2010027875-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2010025295-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152133-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |